Mainly, by signing the orders to late and to to few doses. Which held back extension of the production capacities. In the meantime, a new production site in Ger

Mainly, by signing the orders to late and to to few doses. Which held back extension of the production capacities. In the meantime, a new production site in Germany went operational (Marburg) and increased the output of BioNTech. In Q3 there is probably enough production to supply Germany, but that means at least one more quarter where people and businesses die.